After finishing at $2.95 in the prior trading day, Heron Therapeutics Inc. (NASDAQ: HRTX) closed at $2.83, down -4.07%. In other words, the price has decreased by -$0.1200 from its previous closing price. On the day, 2094385 shares were traded. HRTX stock price reached its highest trading level at $2.9600 during the session, while it also had its lowest trading level at $2.7400.
Our goal is to gain a better understanding of HRTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 6.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on May 27, 2020, initiated with a Buy rating and assigned the stock a target price of $24.
On February 20, 2020, Needham reiterated its Buy rating and also upped its target price recommendation from $50 to $48.
Needham reiterated its Buy rating for the stock on January 16, 2019, while the target price for the stock was revised from $66 to $64.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 03 when MANHARD KIMBERLY sold 1,504 shares for $4.76 per share. The transaction valued at 7,154 led to the insider holds 10,872 shares of the business.
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.42 while its Price-to-Book (P/B) ratio in mrq is 14.15.
Stock Price History:
Over the past 52 weeks, HRTX has reached a high of $9.45, while it has fallen to a 52-week low of $2.19. The 50-Day Moving Average of the stock is 2.7564, while the 200-Day Moving Average is calculated to be 3.6177.
The stock has traded on average 2.56M shares per day over the past 3-months and 1.84M shares per day over the last 10 days, according to various share statistics. A total of 118.89M shares are outstanding, with a floating share count of 118.39M. Shares short for HRTX as of Oct 13, 2022 were 29.18M with a Short Ratio of 25.03M, compared to 32.72M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 24.56% and a Short% of Float of 31.15%.
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.38 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.44, while EPS last year was -$0.51. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.12 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.6 and -$1.94 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$0.79, with 6 analysts recommending between -$0.65 and -$1.
5 analysts predict $26.96M in revenue for the current quarter. It ranges from a high estimate of $29.15M to a low estimate of $25.3M. As of the current estimate, Heron Therapeutics Inc.’s year-ago sales were $23.23M, an estimated increase of 16.10% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $29.28M, an increase of 41.80% over than the figure of $16.10% in the same quarter last year. There is a high estimate of $30.6M for the next quarter, whereas the lowest estimate is $28.2M.
A total of 5 analysts have provided revenue estimates for HRTX’s current fiscal year. The highest revenue estimate was $109.83M, while the lowest revenue estimate was $105.15M, resulting in an average revenue estimate of $107.14M. In the same quarter a year ago, actual revenue was $86.35M, up 24.10% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $160.81M in the next fiscal year. The high estimate is $173.3M and the low estimate is $155.1M. The average revenue growth estimate for next year is up 50.10% from the average revenue estimate for this year.